• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Efficacy and Safety of Using Dual Versus Monotherapy Antiplatelet Agents in Secondary Stroke Prevention: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials
Conclusions: DAPT decreases the risk of recurrent stroke and composite events compared with monotherapy. DAPT increases the risk of major hemorrhage, except if the treatment is limited to 30 days and does not include the combination of aspirin plus ticagrelor.PMID:33926204 | DOI:10.1161/CIRCULATIONAHA.121.053782
Source: Circulation - April 30, 2021 Category: Cardiology Authors: Gabriela Trifan Philip B Gorelick Fernando D Testai Source Type: research

Time Course for Benefit and Risk of Clopidogrel and Aspirin after Acute Transient Ischemic Attack and Minor Ischemic Stroke: A Secondary Analysis from the POINT Randomized Trial.
CONCLUSIONS: The benefit of clopidogrel-aspirin occurs predominantly within the first 21 days, and outweighs the low, but ongoing risk of major hemorrhage. When considered with the results of CHANCE, a similar trial treating with clopidogrel-aspirin for 21 days and showing no increase in major hemorrhage, these results suggest limiting clopidogrel-aspirin use to 21 days may maximize benefit and reduce risk after high-risk TIA or minor ischemic stroke. CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov Unique Identifier: NCT00991029. PMID: 31238700 [PubMed - as supplied by publisher]
Source: Circulation - June 25, 2019 Category: Cardiology Authors: Johnston SC, Elm JJ, Easton JD, Farrant M, Barsan WG, Kim AS, Lindblad AS, Palesch YY, Zurita KG, Albers GW, Cucchiara BL, Kleindorfer DO, Lutsep HL, Pearson C, Sethi P, Vora N, POINT and Neurological Emergencies Treatment Trials Network Investigators Tags: Circulation Source Type: research

Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack (CHANCE): 1-Year Outcomes.
CONCLUSIONS: -The early benefit of clopidogrel-aspirin treatment in reducing the risk of subsequent stroke persisted over the duration of 1 year of follow-up. Clinical Trial Registration Information-www.clinicaltrials.gov. Identifier: NCT00979589. PMID: 25957224 [PubMed - as supplied by publisher]
Source: Circulation - May 8, 2015 Category: Cardiology Authors: Wang Y, Pan Y, Zhao X, Li H, Wang D, Johnston SC, Liu L, Meng X, Wang A, Wang C, Wang Y, CHANCE investigators Tags: Circulation Source Type: research

A Little Good...
Abstract My grandmother used to say: "If a little'll do a little good, a lot'll do a lotta good." Unfortunately, it is not that simple with antiplatelet agents. Many relevant facts are well-established. In identifiable subgroups of patients who present with TIA or minor stroke, the risk of a subsequent stroke is high.(1-3) Most of this risk is incurred during the first few days after a warning event.(2) Aspirin and other antiplatelet agents can lower the risk of secondary stroke by approximately 12-22%.(4,5) In patients with acute coronary syndromes, another thrombotic disorder, dual antiplatelet therapy offers a ...
Source: Circulation - September 12, 2013 Category: Cardiology Authors: Feske SK Tags: Circulation Source Type: research